In pyoderma gangrenosum, a blister or nodule on the skin rapidly expands and forms an ulcer, usually on the leg or trunk. The lesion often is quite tender.

Phase 3 pyoderma gangrenosum trial was halted after analysis of 30 patients showed no efficacy signal. InflaRx to prioritize INF904 with key data expected in chronic spontaneous urticaria and ...

Tumor necrosis factor alpha (TNFα) is a cytokine involved in various activities in the human body (Gottlieb, 2001; Gottlieb & Bos, 2002; Lebwohl, 2003; Williams & Griffiths, 2002).

Pyoderma Gangrenosum: Pain Identified as Reliable Patient-Reported Outcome Doug Brunk September 21, 2023 0 ...

Key takeaways: Ulcerative pyoderma gangrenosum is a rare disease with no current treatment. Vilobelimab has been granted orphan drug and fast track designations by the FDA. InflaRx has initiated a ...

Multi-national, randomized, controlled adaptive Phase III design for vilobelimab in ulcerative pyoderma gangrenosum (PG) Trial size to be adapted upon interim analysis with planned total patient ...

Multi-national, randomized, controlled adaptive Phase III study in ulcerative pyoderma gangrenosum (PG) initiated and first patient dosed in the U.S. PG is a rare and debilitating autoimmune skin ...

Pain as a patient-reported outcome measure during the treatment of pyoderma gangrenosum may indicate whether a patient is responding to treatment, according to a research letter published in JAMA ...

SPOKANE, Wash. – Ryan Becker, a Spokane resident, is battling an extremely rare skin condition known as pyoderma gangrenosum. After visits to the Mayo Clinic and Johns Hopkins, Becker has been ...